These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26996311)

  • 1. A comparison of secondary prevention practice in poststroke and coronary heart disease patients.
    Vaněk J; Mayer O; Seidlerová J; Bruthans J; Kielbergerová L; Wohlfahrt P; Krajčoviechová A; Filipovský J; Cífková R
    Public Health; 2016 Aug; 137():64-72. PubMed ID: 26996311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.
    EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events
    Lancet; 2001 Mar; 357(9261):995-1001. PubMed ID: 11293642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing secondary prevention for patients with coronary heart disease and stroke attending Australian general practices: a cross-sectional study using nationwide electronic database.
    Yue J; Kazi S; Nguyen T; Chow CK
    BMJ Qual Saf; 2024 Jul; 33(8):499-510. PubMed ID: 37487712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure control and risk profile in poststroke survivors: a comparison with the general population.
    Cífková R; Wohlfahrt P; Krajčoviechová A; Jozífová M; Mayer O; Vaněk J; Hlinovský D; Kielbergerová L; Lánská V
    J Hypertens; 2015 Oct; 33(10):2107-14. PubMed ID: 26200884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey.
    Heuschmann PU; Kircher J; Nowe T; Dittrich R; Reiner Z; Cifkova R; Malojcic B; Mayer O; Bruthans J; Wloch-Kopec D; Prugger C; Heidrich J; Keil U
    Eur J Prev Cardiol; 2015 Oct; 22(10):1354-62. PubMed ID: 25139770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology.
    Gyberg V; De Bacquer D; De Backer G; Jennings C; Kotseva K; Mellbin L; Schnell O; Tuomilehto J; Wood D; Rydén L; Amouyel P; Bruthans J; Conde AC; Cifkova R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pająk A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D;
    Cardiovasc Diabetol; 2015 Oct; 14():133. PubMed ID: 26427624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in China.
    Peng B; Ni J; Anderson CS; Zhu Y; Wang Y; Pu C; Wu J; Wang J; Zhou L; Yao M; He J; Shan G; Gao S; Xu W; Cui L;
    Stroke; 2014 Feb; 45(2):515-9. PubMed ID: 24385269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of secondary medical prophylaxis and clinical outcome among patients with ischemic stroke: a nationwide follow-up study.
    Palnum KH; Mehnert F; Andersen G; Ingeman A; Krog BR; Bartels PD; Johnsen SP
    Stroke; 2012 Mar; 43(3):802-7. PubMed ID: 22207506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey on compliance with secondary stroke prevention guidelines and follow up for the inpatients with atherosclerotic cerebral infarction/transient ischemic attack.
    Ma R; Wang C; Zhao X; Xu M; Lv Y; Wei M; Cai Y; Zhang Z; Wang L; Zhang W; Huang Y; Li Y; Li H; Wang Y
    Neurol Res; 2008 May; 30(4):383-8. PubMed ID: 18544256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis at 6 months for coronary and cerebrovascular patients: impact of antiplatelet agents and statins: results from the Prevenir III study.
    Ferrières J; Cambou JP; Cantet C; Guize L
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):55-61. PubMed ID: 16552472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey.
    Prugger C; Keil U; Wellmann J; de Bacquer D; de Backer G; Ambrosio GB; Reiner Z; Gaita D; Wood D; Kotseva K; Heidrich J;
    J Hypertens; 2011 Aug; 29(8):1641-8. PubMed ID: 21720270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project.
    Niu S; Zhao D; Zhu J; Liu J; Liu Q; Liu J; Wang W; Smith SC;
    Am Heart J; 2009 Apr; 157(4):709-15.e1. PubMed ID: 19332200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary Prevention in Younger vs. Older Coronary Heart Disease Patients-Insights from the German Subset of the EUROASPIRE IV Survey.
    Wagner M; Gelbrich G; Kircher J; Kotseva K; Wood D; Morbach C; Leyh R; Ertl G; Karmann W; Störk S; Heuschmann PU
    Int J Behav Med; 2018 Jun; 25(3):283-293. PubMed ID: 29086252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke.
    Glader EL; Sjölander M; Eriksson M; Lundberg M
    Stroke; 2010 Feb; 41(2):397-401. PubMed ID: 20075360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders.
    Zupanic E; Kramberger MG; von Euler M; Norrving B; Winblad B; Secnik J; Fastbom J; Eriksdotter M; Garcia-Ptacek S
    J Alzheimers Dis; 2020; 73(3):1013-1021. PubMed ID: 31884483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
    Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Hoffman E; Goto S; Ohman EM; Bhatt DL;
    Am J Med; 2013 Aug; 126(8):693-700.e1. PubMed ID: 23800583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.
    Eur Heart J; 1997 Oct; 18(10):1569-82. PubMed ID: 9347267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for inequalities in the management of coronary heart disease in Scotland.
    Simpson CR; Hannaford PC; Williams D
    Heart; 2005 May; 91(5):630-4. PubMed ID: 15831649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.